tradingkey.logo
tradingkey.logo
Suchen

Illumina Inc

ILMN
Zur Watchlist hinzufügen
145.475USD
-0.225-0.15%
Trading geöffnet ETKurse um 15 Minuten verzögert
22.11BMarktkapitalisierung
26.28KGV TTM

mehr Informationen über Illumina Inc Unternehmen

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.

Illumina Inc Informationen

BörsenkürzelILMN
Name des UnternehmensIllumina Inc
IPO-datumJun 28, 2000
CEOThaysen (Jacob)
Anzahl der mitarbeiter8970
WertpapierartOrdinary Share
GeschäftsjahresendeJun 28
Addresse5200 Illumina Way
StadtSAN DIEGO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92122
Telefon18582024500
Websitehttps://www.illumina.com
BörsenkürzelILMN
IPO-datumJun 28, 2000
CEOThaysen (Jacob)

Führungskräfte von Illumina Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jacob Thaysen, Ph.D.
Mr. Jacob Thaysen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
40.31K
+38.25%
Dr. Steven (Steve) Barnard, Ph.D.
Dr. Steven (Steve) Barnard, Ph.D.
Chief Technology Officer
Chief Technology Officer
22.38K
+25.25%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
22.14K
--
Dr. Frances H. Arnold, Ph.D.
Dr. Frances H. Arnold, Ph.D.
Independent Director
Independent Director
20.91K
-0.57%
Mr. Philip W. (Phil) Schiller
Mr. Philip W. (Phil) Schiller
Independent Director
Independent Director
20.15K
--
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Independent Director
Independent Director
16.43K
--
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Director
Independent Director
15.19K
--
Ms. Susan E. (Sue) Siegel
Ms. Susan E. (Sue) Siegel
Independent Director
Independent Director
14.46K
--
Mr. Kevin Pegels
Mr. Kevin Pegels
Chief of Global Operations
Chief of Global Operations
13.13K
+37.39%
Mr. Ankur Dhingra
Mr. Ankur Dhingra
Chief Financial Officer
Chief Financial Officer
13.05K
+36.02%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jacob Thaysen, Ph.D.
Mr. Jacob Thaysen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
40.31K
+38.25%
Dr. Steven (Steve) Barnard, Ph.D.
Dr. Steven (Steve) Barnard, Ph.D.
Chief Technology Officer
Chief Technology Officer
22.38K
+25.25%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
22.14K
--
Dr. Frances H. Arnold, Ph.D.
Dr. Frances H. Arnold, Ph.D.
Independent Director
Independent Director
20.91K
-0.57%
Mr. Philip W. (Phil) Schiller
Mr. Philip W. (Phil) Schiller
Independent Director
Independent Director
20.15K
--
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Independent Director
Independent Director
16.43K
--

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Consumables
3.23B
74.30%
Services and Other revenue
634.00M
14.60%
Instruments
482.00M
11.10%
Nach RegionUSD
Name
Umsatz
Anteil
United States
2.24B
51.65%
Europe
1.26B
29.10%
Asia, Middle East, and Africa
430.00M
9.90%
Greater China
243.00M
5.60%
Americas
163.00M
3.75%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Consumables
3.23B
74.30%
Services and Other revenue
634.00M
14.60%
Instruments
482.00M
11.10%

Aktionärsstatistik

Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Capital World Investors
13.29%
BlackRock Institutional Trust Company, N.A.
8.69%
Vanguard Portfolio Management, LLC
4.51%
Vanguard Capital Management, LLC
4.36%
State Street Investment Management (US)
4.09%
Andere
65.06%
Aktionäre
Aktionäre
Anteil
Capital World Investors
13.29%
BlackRock Institutional Trust Company, N.A.
8.69%
Vanguard Portfolio Management, LLC
4.51%
Vanguard Capital Management, LLC
4.36%
State Street Investment Management (US)
4.09%
Andere
65.06%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
62.42%
Investment Advisor/Hedge Fund
26.91%
Hedge Fund
10.15%
Pension Fund
3.23%
Research Firm
2.53%
Bank and Trust
1.87%
Sovereign Wealth Fund
0.41%
Family Office
0.33%
Individual Investor
0.21%

Institutionelle Beteiligung

Aktualisiert: Sun, Apr 5
Aktualisiert: Sun, Apr 5
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
1879
162.52M
107.41%
-15.36M
2025Q4
1874
161.12M
105.45%
-20.88M
2025Q3
1888
158.57M
103.78%
-23.77M
2025Q2
1978
167.87M
109.04%
-18.11M
2025Q1
2072
170.79M
107.89%
-16.32M
2024Q4
2074
166.23M
104.94%
-15.71M
2024Q3
2038
151.41M
95.06%
-11.30M
2024Q2
2033
149.41M
93.80%
-18.06M
2024Q1
2096
153.02M
96.09%
-8.97M
2023Q4
2134
150.48M
94.76%
-5.28M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Capital World Investors
20.10M
13.15%
+124.32K
+0.62%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
13.15M
8.6%
+8.91K
+0.07%
Dec 31, 2025
State Street Investment Management (US)
6.19M
4.05%
+190.32K
+3.17%
Dec 31, 2025
WCM Investment Management
4.07M
2.66%
-110.36K
-2.64%
Dec 31, 2025
AQR Capital Management, LLC
4.43M
2.89%
+1.03M
+30.26%
Dec 31, 2025
Loomis, Sayles & Company, L.P.
4.17M
2.73%
-115.71K
-2.70%
Dec 31, 2025
Corvex Management LP
3.83M
2.5%
--
--
Dec 31, 2025
Sessa Capital
3.40M
2.23%
-1.28M
-27.37%
Dec 31, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco Biotechnology & Genome ETF
6.09%
Global X Genomics & Biotechnology ETF
5.58%
First Trust Nasdaq Lux Digi Health Solutions ETF
4.96%
First Trust NYSE Arca Biotechnology Index Fund
4.42%
ARK Genomic Revolution ETF
4.38%
VanEck Biotech ETF
3.09%
Alger Russell Innovation ETF
2.61%
First Trust NASDAQ Pharmaceuticals ETF
2.39%
iShares Health Innovation Active ETF
2.29%
First Trust Health Care Alphadex Fund
2.27%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil6.09%
Global X Genomics & Biotechnology ETF
Anteil5.58%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil4.96%
First Trust NYSE Arca Biotechnology Index Fund
Anteil4.42%
ARK Genomic Revolution ETF
Anteil4.38%
VanEck Biotech ETF
Anteil3.09%
Alger Russell Innovation ETF
Anteil2.61%
First Trust NASDAQ Pharmaceuticals ETF
Anteil2.39%
iShares Health Innovation Active ETF
Anteil2.29%
First Trust Health Care Alphadex Fund
Anteil2.27%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI